U.S. pharmaceutical, health care and other life sciences companies are increasingly seen as potential targets of acquisition, not only by stronger domestic competitors, but also by overseas rivals in Japan in particular. The relatively weak dollar and increased downside risk from the current global financial crisis have made U.S. firms attractive buys.
Wendy Goldstein (Member of the Firm and Pharmaceutical Practice Group Leader, Epstein Becker Green), Scott Minars (Partner, Merger & Acquisition Services, Deloitte & Touche LLP) and Lynn Shapiro Snyder (Member of the Firm; Co-Chair, Health Care Fraud Practice Group; and Chair, Third Party Payment Practice Group, Epstein Becker Green), and moderator Michael A. Levine (Member of the Firm and Head of the CSR/Sustainability Practice, Epstein Becker Green) will examine recent industry deals involving Japanese firms and share demographic insights into the future of the U.S. health care industry. They will identify high risk topics for pharmaceutical firms in health regulatory due diligence and discuss recent federal health care legislative activities that will affect M&A activities in the U.S. health care industry.
